PPARG and metabolic dysfunction-associated steatotic liver disease: A recent study suggested that hepatocyte SHP1 might affect peroxisome proliferator–activated receptor gamma- (PPARγ-) mediated hepatic inflammation by presenting obesity-induced NAFLD [15].